Media

Racura Oncology CEO Dr Daniel Tillett spoke with Proactive about the activation of the company’s first clinical site in Hong Kong for its Phase 1 RC220 trial in advanced solid tumours. Located at Queen Mary Hospital, this marks the start of patient enrolment in the region, with screening underway and the first patient expected to…

We are pleased to share another instalment of our “Inside Racura” video interview series, introducing Chief Medical Officer Dr Jose Iglesias, who joined the Racura Oncology team in May 2025. Dr Iglesias shares what first attracted him to the field of oncology and walks us through his distinguished 36-year career as a pharmaceutical executive. He…

Stockhead‘s Tim Boreham has reported on Racura Oncology announcing the site activation of Queen Mary Hospital in Hong Kong, enabling the commencement of patient recruitment for Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumour patients. The company hopes that as well as attacking the tumours, RC220 will protect the…

Samso’s Noel Ong has compiled the key highlights of Racura Oncology in this note, and outlined the upcoming inflection points for the company. In his analysis, Mr Ong writes: “Most of us have known someone who is in the predicament of being a patient of some form of cancer, so the path to finding a…

Racura Oncology has announced the results of the Phase 2 clinical trial of RC110 bisantrene for relapsed or refractory acute myeloid leukaemia (AML) has been published in the peer-reviewed British Journal of Haematology, as reported by Biotech Dispatch. Read the full article here.

Racura Oncology chief executive officer Dr Daniel Tillett talked with Proactive about the company’s key milestones this quarter, including the treatment of the first patient with its lead asset, RC220, a reformulated version of bisantrene. Watch the full interview here.

In this exclusive interview with The Capital Compass, Dr. Pete Smith from Racura Oncology discusses the company’s groundbreaking work on RC220, a reformulated cancer drug with a proven history of efficacy and safety. Watch the full interview here.

Racura Oncology Ltd (ASX:RAC, OTC:RAONF) has successfully dosed the first patient with the combination of its lead drug RC220 and doxorubicin in its Phase 1 clinical trial targeting advanced solid tumours.  Read the full article here.

The Australian reports Racura Oncology has achieved a major milestone, as the company has safely and successfully dosed its first patients for its Phase 1 clinical trial in advanced solid tumours. Read the full report here.